Strategies to optimize the prevention and treatment of DM and CKD in HF and to translate the recent promising sodium-glucose cotransporter 2 trial results into real-world patient benefit are urgently required.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: People with DM, CKD, and HF are at high risk, requiring close consideration of comorbidity management. This evidence concerns the gene SLC5A2 and chronic kidney disease.